Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis

Anthony Matta; Vanina Bongard; Frédéric Bouisset; Dorota Taraszkiewicz; Jean-Pierre Rabès; Jean Ferrières

doi:10.12659/MSM.928784

07 May 2021: Clinical Research

Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis

Anthony Matta ^123ABCDEF , Vanina Bongard ^12ABCDEF , Frédéric Bouisset ^12ABCDEF , Dorota Taraszkiewicz ^12ABCDEF , Jean-Pierre Rabès ^4BDEF , Jean Ferrières ^12ABCDEFG*

DOI: 10.12659/MSM.928784

Med Sci Monit 2021; 27:e928784

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Figure 1 Low-density lipoprotein cholesterol reduction (%) from the baseline after PCSK9i initiation. PCSK9i – proprotein convertase subtilisin/kexin type 9 inhibitor.

Back to the Article

Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis

Your Privacy